Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials
| العنوان: | Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials |
|---|---|
| المؤلفون: | Richard B Lipton, Andrew Blumenfeld, Christopher M Jensen, Robert Croop, Alexandra Thiry, Gilbert L’Italien, Beth A Morris, Vladimir Coric, Peter J Goadsby |
| المصدر: | Cephalalgia. 43:033310242211416 |
| بيانات النشر: | SAGE Publications, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Neurology (clinical), General Medicine |
| الوصف: | Background This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg — an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive treatment of migraine — assessed efficacy in adults with migraine based on triptan treatment experience. Methods Participants were assigned to one of four groups based on triptan treatment experience: insufficient response (e.g. lack of efficacy and/or poor tolerability) to 1 triptan, insufficient response to ≥2 triptans, current triptan users, and triptan-naïve participants. The co-primary efficacy endpoints were pain freedom and most bothersome symptom freedom at two hours postdose. Results In the three trials (N = 3507; rimegepant n = 1749, placebo n = 1758), 1235 (35.2%) participants had a history of insufficient response to 1 triptan (n = 910 [25.9%]) or ≥2 triptans (n = 325 [9.3%]), and 2272 (64.8%) had no history of insufficient response to triptans (current use = 595 [17.0%], naïve = 1677 [47.8%]). Rimegepant was effective on the co-primary endpoints in all subgroups ( p ≤ 0.013), except for freedom from the most bothersome symptom in the triptan-naïve group ( p = 0.06). No differences on co-primary endpoints were found in pairwise comparisons of rimegepant-treated participants. Conclusions Rimegepant was effective for the acute treatment of migraine in adults with a history of insufficient response to 1 or ≥2 triptans and in current triptan users. Efficacy on co-primary endpoints did not differ based on the number of insufficient triptan responses. Trial registration: Clinicaltrials.gov: NCT03235479, NCT03237845, NCT03461757 |
| تدمد: | 1468-2982 0333-1024 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::e7a97d72f08f8119bf92fcb56f51ceccTest https://doi.org/10.1177/03331024221141686Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........e7a97d72f08f8119bf92fcb56f51cecc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14682982 03331024 |
|---|